emavusertib,nivolumab,pembrolizumab
merck,bms,curis
['nivo', 'pembro', 'ca-4948', 'nivolumab', 'gastric', 'emavusertib', '$cris']
$cris at #asco2022 emavusertib (ca-4948) in combination with folfox chemotherapy plus nivolumab or pembrolizumab for gastric ca. preclinically established that chemotherapy resistance can be driven by tlr9 activation and irak4 dependent activation of pro-survival nf-kb signaling.
Opinions?? AdvocateInvestor: Cannabis ??/ Blockchain ???????/ Psychedelics ??/ Green-future ??/ Biotech ?? *Trading assets for time; our most precious resource*